JP7712496B2 - 抗cd39抗体及びその使用 - Google Patents

抗cd39抗体及びその使用

Info

Publication number
JP7712496B2
JP7712496B2 JP2024552127A JP2024552127A JP7712496B2 JP 7712496 B2 JP7712496 B2 JP 7712496B2 JP 2024552127 A JP2024552127 A JP 2024552127A JP 2024552127 A JP2024552127 A JP 2024552127A JP 7712496 B2 JP7712496 B2 JP 7712496B2
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
sequence identity
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024552127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508956A (ja
Inventor
エリザベス バウマン,クリスティン
ペイ シァン チェン,アダ
フェルナンデス-サラス,エスター
ペルハム クリントン ウォルカー,ナイジェル
ザオ,シァオニン
フ,ヤオファ
ニー,シーウィー
グ,ジジェ
Original Assignee
アーカス バイオサイエンシズ インコーポレイティド
ウーシー バイオロジクス アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2022/079021 external-priority patent/WO2023164872A1/en
Application filed by アーカス バイオサイエンシズ インコーポレイティド, ウーシー バイオロジクス アイルランド リミテッド filed Critical アーカス バイオサイエンシズ インコーポレイティド
Publication of JP2025508956A publication Critical patent/JP2025508956A/ja
Priority to JP2025116414A priority Critical patent/JP2025148452A/ja
Application granted granted Critical
Publication of JP7712496B2 publication Critical patent/JP7712496B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024552127A 2022-03-03 2023-03-02 抗cd39抗体及びその使用 Active JP7712496B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116414A JP2025148452A (ja) 2022-03-03 2025-07-10 抗cd39抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2022/079021 WO2023164872A1 (en) 2022-03-03 2022-03-03 Anti-cd39 antibodies and use thereof
CNPCT/CN2022/079021 2022-03-03
CN2022126070 2022-10-19
CNPCT/CN2022/126070 2022-10-19
PCT/CN2023/079295 WO2023165561A1 (en) 2022-03-03 2023-03-02 Anti-cd39 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116414A Division JP2025148452A (ja) 2022-03-03 2025-07-10 抗cd39抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2025508956A JP2025508956A (ja) 2025-04-10
JP7712496B2 true JP7712496B2 (ja) 2025-07-23

Family

ID=87883061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024552127A Active JP7712496B2 (ja) 2022-03-03 2023-03-02 抗cd39抗体及びその使用
JP2025116414A Pending JP2025148452A (ja) 2022-03-03 2025-07-10 抗cd39抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116414A Pending JP2025148452A (ja) 2022-03-03 2025-07-10 抗cd39抗体及びその使用

Country Status (13)

Country Link
US (2) US11970543B2 (cg-RX-API-DMAC7.html)
EP (1) EP4486785A4 (cg-RX-API-DMAC7.html)
JP (2) JP7712496B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240156633A (cg-RX-API-DMAC7.html)
CN (2) CN119173535A (cg-RX-API-DMAC7.html)
AR (1) AR128688A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023227964A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253669A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002620A1 (cg-RX-API-DMAC7.html)
IL (1) IL315351A (cg-RX-API-DMAC7.html)
MX (1) MX2024010646A (cg-RX-API-DMAC7.html)
TW (1) TW202340243A (cg-RX-API-DMAC7.html)
WO (1) WO2023165561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260191954A1 (en) * 2022-12-01 2026-07-09 Innate Pharma Compositions and methods for neoadjuvant treatment in cancer
CN119798442B (zh) * 2023-12-27 2025-12-16 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
US20160137747A1 (en) 2008-01-31 2016-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
WO2018167267A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
JP2019509014A (ja) 2015-11-23 2019-04-04 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. Cd39血管アイソフォームターゲティング剤
CN112714768A (zh) 2019-08-27 2021-04-27 科望(苏州)生物医药科技有限公司 新型抗cd39抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US11376269B2 (en) 2016-05-06 2022-07-05 Inserm Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
AU2018346447B2 (en) 2017-10-06 2025-06-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
IL273440B1 (en) 2017-11-15 2026-08-01 Innate Pharma Strengthening the effect of ATP release
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
EP3806902A4 (en) 2018-06-14 2022-05-04 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
MX2021010119A (es) 2019-02-21 2021-12-10 Trishula Therapeutics Inc Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
WO2021203058A2 (en) 2020-04-03 2021-10-07 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
US20240052061A1 (en) 2020-09-10 2024-02-15 Purinomia Biotech, Inc. Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
EP4251650A4 (en) 2020-11-27 2024-10-23 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160137747A1 (en) 2008-01-31 2016-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
US20170335007A1 (en) 2014-11-07 2017-11-23 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
JP2019509014A (ja) 2015-11-23 2019-04-04 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. Cd39血管アイソフォームターゲティング剤
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
WO2018167267A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
CN112714768A (zh) 2019-08-27 2021-04-27 科望(苏州)生物医药科技有限公司 新型抗cd39抗体

Also Published As

Publication number Publication date
CA3253669A1 (en) 2023-09-07
IL315351A (en) 2024-11-01
CN119569881A (zh) 2025-03-07
US20240034803A1 (en) 2024-02-01
AU2023227964A1 (en) 2024-09-19
JP2025508956A (ja) 2025-04-10
CN119173535A (zh) 2024-12-20
US11970543B2 (en) 2024-04-30
JP2025148452A (ja) 2025-10-07
TW202340243A (zh) 2023-10-16
WO2023165561A1 (en) 2023-09-07
EP4486785A1 (en) 2025-01-08
CN119569881B (zh) 2025-11-07
KR20240156633A (ko) 2024-10-30
AR128688A1 (es) 2024-06-05
EP4486785A4 (en) 2026-07-08
CL2024002620A1 (es) 2025-01-03
MX2024010646A (es) 2024-09-19
US20250084178A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2021247591A1 (en) Antibodies to tigit
KR20210030925A (ko) 메소텔린 및 cd137 결합 분자
EP3380523A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US11970543B2 (en) Anti-CD39 antibodies and use thereof
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
US20250179176A1 (en) Anti-tigit antibodies and uses of the same
KR20240038008A (ko) 암 치료 방법 및 조성물
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
HK40124330A (en) Anti-cd39 antibodies and use thereof
HK40124330B (en) Anti-cd39 antibodies and use thereof
HK40113788A (en) Anti-cd39 antibodies and use thereof
EP4055052A1 (en) Methods of treating cancer with anti-pd-1 antibodies
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40122875A (en) Anti-tigit antibodies and uses of the same
HK40079159A (en) Methods of treating cancer with anti-pd-1 antibodies
JP2025539459A (ja) 癌におけるネオアジュバント処置のための組成物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241120

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250710

R150 Certificate of patent or registration of utility model

Ref document number: 7712496

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150